Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714056 | 0.80 | KDM4E (0.37) | TLR8TLR7PIK3CDKDM4EALDH1A1 | |
| SCHEMBL3714054 | 0.80 | KDM4E (0.37) | TLR8TLR7PIK3CDKDM4EALDH1A1 | |
| SCHEMBL864207 | 0.78 | ALDH1A1 (0.38) | TLR8TLR7PIK3CDKDM4EALDH1A1 | |
| SCHEMBL864209 | 0.78 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL15184782 | 0.76 | KDM4E (0.35) | TLR8TLR7PIK3CDKDM4E | |
| SCHEMBL15184778 | 0.76 | HTR7 (0.39) | TLR8TLR7PIK3CDKDM4EALDH1A1 | |
| SCHEMBL864178 | 0.76 | HTR7 (0.39) | TLR8TLR7PIK3CDKDM4EALDH1A1 | |
| SCHEMBL863915 | 0.73 | CDK5 (0.39) | KDM4EALDH1A1RXFP1 | |
| SCHEMBL864177 | 0.71 | PIK3CD (0.32) | PIK3CDKDM4EALDH1A1RXFP1 | |
| SCHEMBL864127 | 0.71 | HTR7 (0.38) | TLR8TLR7PIK3CDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | TLR8 1947/4885TLR7 1153/4885PIK3CD 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.